STOCK TITAN
  1. Home
  2. Sec-filings
  3. LKFT
  4. [6-K] Lakefront Biotherapeutics NV Current Report (Foreign Issuer)

Lakefront buys back €3.2M in stock at €25.19

From Aug. 24–28, Lakefront repurchased 127,796 shares for €3.22M at a €25.19 average, leaving it with 1,161,324 shares held as of Aug. 28 close.

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Lakefront Biotherapeutics NV (LKFT) reported recent activity under its ordinary share repurchase program announced on June 9, 2026. Between August 24 and August 28, 2026, the company repurchased 127,796 shares through a discretionary mandate to an independent financial intermediary across several European trading venues.

The average price paid was €25.19 per share, for an aggregate consideration of €3,218,710.15, with individual trades executed between €24.36 and €25.66 per share. As of market close on August 28, 2026, Lakefront held 1,161,324 of its own ordinary shares.

Positive

  • None.

Negative

  • None.
Shares repurchased 127,796 shares Ordinary shares repurchased between August 24 and August 28, 2026
Average price paid €25.19 per share Average repurchase price for 127,796 shares
Total consideration €3,218,710.15 Aggregate amount spent on share repurchases August 24–28, 2026
Lowest price paid €24.36 per share Lowest price for any repurchased share in the period
Highest price paid €25.66 per share Highest price for any repurchased share in the period
Treasury shares held 1,161,324 shares Own ordinary shares held as of market close on August 28, 2026
Press release time 22.01 CET Time of publication on September 1, 2026 in Mechelen, Belgium
repurchase program financial
"Within the framework of the repurchase program announced on June 9, 2026"
A repurchase program is when a company buys back its own shares from the open market. This reduces the total number of shares available, which can increase the value of each remaining share and signal confidence in the company's future. For investors, it often suggests that the company believes its stock is undervalued and can be a sign of financial strength.
discretionary mandate financial
"repurchased 127,796 Lakefront shares via a discretionary mandate"
independent financial intermediary financial
"via a discretionary mandate to an independent financial intermediary"
BCMAxCD3 T‑cell engager medical
"anchored by gamgertamig, a potential first‑in‑class and best-in-class BCMAxCD3 T‑cell engager"
forward-looking statements regulatory
"This press release contains forward-looking statements within the meaning"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

FAQ

What did Lakefront Biotherapeutics (LKFT) announce in its September 2026 Form 6-K?
Lakefront Biotherapeutics announced that, under its share repurchase program, it bought back 127,796 ordinary shares between August 24 and 28, 2026, at an average price of €25.19 per share, for total consideration of €3,218,710.15.

Over what period did LKFT repurchase 127,796 shares and on which venues?
Lakefront repurchased 127,796 shares from August 24 to August 28, 2026 across multiple venues, including XAMS, TQEX, CEUX, and AQEU, using a discretionary mandate to an independent financial intermediary.

What was the total amount spent by LKFT on share repurchases in this period?
During the August 24–28, 2026 window, Lakefront spent a total of €3,218,710.15 repurchasing 127,796 ordinary shares under its previously announced share repurchase program.

What was the average and price range paid per LKFT share in the buyback?
The company reported an average price of €25.19 per share for the repurchases. The lowest price paid was €24.36 per share and the highest price paid was €25.66 per share during the period.

How many LKFT shares does Lakefront Biotherapeutics hold after these repurchases?
As of market close on August 28, 2026, following the reported repurchases, Lakefront Biotherapeutics held 1,161,324 of its own ordinary shares.

What is the focus of Lakefront Biotherapeutics’ pipeline mentioned alongside the buyback?
Lakefront Biotherapeutics has a clinical‑stage portfolio in immunology and inflammation, anchored by gamgertamig, described as a potential first‑in‑class and best‑in‑class BCMAxCD3 T‑cell engager for autoimmune diseases.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2026

Commission File Number: 001-37384

Lakefront Biotherapeutics
(Translation of registrant's name into English)

Schaliënhoevedreef 20T, 2800 Mechelen, Belgium
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

The information contained in this Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333- 218160, 333-225263, 333-231765, 333-249416, 333-260500, 333-268756, 333-275886, 333-283361, and 333-292050).

On September 1, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Exhibit 99.1. Press release dated September 1, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

      Lakefront Biotherapeutics    
  (Registrant)
   
  
Date: September 1, 2026     /s/ Ying Deng    
  Ying Deng
  Authorized Officer
  

EXHIBIT 99.1

Acquisition of Own Shares

Mechelen, Belgium; 01 September 2026, 22.01 CET; regulated information

Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between August 24, 2026 and August 28, 2026 it has repurchased 127,796 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows:

Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€)
24/08/2026 XAMS 21,820 24.56 535,857.74 24.36 24.64
24/08/2026 TQEX 450 24.55 11,045.43 24.54 24.60
24/08/2026 CEUX 328 24.58 8,062.37 24.54 24.64
24/08/2026 AQEU 1,333 24.61 32,811.40 24.58 24.66
25/08/2026 XAMS 21,058 25.29 532,464.16 24.94 25.52
25/08/2026 TQEX 698 25.25 17,623.66 25.00 25.36
25/08/2026 CEUX 600 25.28 15,165.48 25.24 25.34
25/08/2026 AQEU 313 25.29 7,914.33 25.26 25.34
26/08/2026 XAMS 22,968 25.45 584,632.07 25.08 25.64
26/08/2026 TQEX 599 25.45 15,241.91 25.30 25.64
26/08/2026 CEUX 1,703 25.47 43,377.62 25.24 25.66
26/08/2026 AQEU 539 25.50 13,744.72 25.32 25.60
27/08/2026 XAMS 21,382 25.27 540,406.53 25.06 25.36
27/08/2026 TQEX 904 25.27 22,843.72 25.20 25.32
27/08/2026 CEUX 2,342 25.24 59,114.89 25.12 25.36
27/08/2026 AQEU 440 25.23 11,100.50 25.12 25.34
28/08/2026 XAMS 25,694 25.29 649,927.16 25.00 25.50
28/08/2026 TQEX 1,110 25.40 28,194.11 25.36 25.46
28/08/2026 CEUX 3,363 25.38 85,342.18 25.08 25.46
28/08/2026 AQEU 152 25.26 3,840.17 25.14 25.46
Total   127,796 25.19 3,218,710.15 24.36 25.66

As of market close on 28 August 2026, Lakefront holds 1,161,324 of its own ordinary shares.

About Lakefront Biotherapeutics
Lakefront Biotherapeutics is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical‑stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class and best-in-class BCMAxCD3 T‑cell engager for autoimmune diseases. Backed by deep deal‑making expertise, operational flexibility, and a strong capital position, Lakefront identifies, acquires, and advances high‑quality assets with clear potential to deliver meaningful patient impact and long‑term shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.

For further information, contact Lakefront Biotherapeutics:
Investor Relations
Sherri Spear
+1 412 522 6418
sherri.spear@lakefrontbio.com

Forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “seek,” “upcoming,” “future,” “estimate,” “may,” “will,” “could,” “would,” “potential,” “forward,” “goal,” “next,” “continue,” “should,” “encouraging,” “aim,” “progress,” “remain,” “explore,” and “further,” as well as similar expressions. These statements include, but are not limited to, statements regarding Lakefront’s plans to repurchase its ordinary shares. Lakefront cautions the reader that forward-looking statements are based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity, performance, or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if our results, performance, financial condition and liquidity, and the development of the industry in which Lakefront operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, those risks and uncertainties that can be found in our filings and reports with the Securities and Exchange Commission (“SEC”), including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC. Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if the result of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking statements in this release to reflect any change in our expectations or any change in events, conditions or circumstances, unless specifically required by law or regulation.

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases